AI Article Synopsis
- The peritoneal carcinomatosis (PC) is increasingly common due to GI and gynecological cancers and has a poorer prognosis than other metastases.
- The study aimed to analyze how the peritoneal carcinomatosis index (PCI) impacts overall survival (OS) and recurrence-free survival (RFS) in patients undergoing cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC).
- Results showed that patients with ovarian tumors and pseudomyxoma with a PCI less than 15 had significantly better OS (over 70 months) compared to those with gastric tumors (only 4 months), indicating that both PCI and tumor type are important predictors of patient survival.
Article Abstract
Background: The peritoneal carcinomatosis (PC) secondary to gastrointestinal or gynecological cancer has increased its incidence. It has a worse prognosis compared to other sites of metastasis. The peritoneal carcinomatosis index (PCI) establishes overall survival in patients with gastrointestinal or gynecological tumors and carcinomatosis.
Objective: To evaluate the relationship of PCI to overall survival (OS) and recurrence-free survival (RFS) in patients treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC).
Method: A descriptive, retrolective study of 80 charts of patients with CP was conducted. We included patients with colon, ovarian, appendicular, pseudomyxoma and gastric tumors with CP treated with CRS plus HIPEC. The OS and RFS were determined according to the type of adenocarcinoma and the degree of differentiation. The OS and RFS were determined in months in patients with PCI > 15 PCI as well as in patients with PCI < 15 considering the tumor of origin.
Results: Patients with ovarian tumors and pseudomyxoma with PCI < 15 presented OS > 70 months, compared to patients with gastric tumors (4 months).
Conclusions: The PCI and histology are predictors of OS. Patients with ovarian tumors and PCI < 15 have higher OS, similar to pseudomyxomas. RFS was also higher in patients with PCI < 15.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.24875/CIRU.22000272 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk Factors for Anastomotic Leakage: A Comprehensive Single-Center Analysis of Colorectal Anastomoses for Ovarian and Gastrointestinal Cancers.
Ann Surg Oncol
January 2025
Department Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Background: Anastomotic leakage (AL) is a major complication in colorectal surgery, particularly following rectal cancer surgery, necessitating effective prevention strategies. The increasing frequency of colorectal resections and anastomoses during cytoreductive surgery (CRS) for peritoneal carcinomatosis further complicates this issue owing to the diverse patient populations with varied tumor distributions and surgical complexities. This study aims to assess and compare AL incidence and associated risk factors across conventional colorectal cancer surgery (CRC), gastrointestinal CRS (GI-CRS), and ovarian CRS (OC-CRS), with a secondary focus on evaluating the role of protective ostomies.
View Article and Find Full Text PDFCytoreductive surgery and HIPEC with oxaliplatin for the treatment of peritoneal carcinomatosis from recurrent fibrolamellar carcinoma.
BMJ Case Rep
January 2025
General Surgery, Hospital Universitario HM Sanchinarro, Madrid, Spain
Fibrolamellar hepatocellular carcinoma (FHCC) is a rare variant of hepatocellular carcinoma (HCC), characterised by a poorer prognosis in later stages compared with conventional HCC due to a high rate of local recurrence, lymph node metastasis and peritoneal metastasis. Conventional chemotherapy is generally ineffective, making surgery the only potentially curative treatment. Currently, surgery is also indicated in cases of recurrence, always aiming for an R0 resection.
View Article and Find Full Text PDFTertiary lymphoid structures in high-grade serous tubo-ovarian carcinoma: anatomical site matters.
Cancer Immunol Immunother
January 2025
Division of Oncology, Department of Clinical Sciences Lund, and Lund University Cancer Center, Lund University, Lund, Sweden.
Tertiary lymphoid structures (TLS) in the tumor microenvironment are prognostically beneficial in many solid cancer types. Reports on TLS in high-grade serous tubo-ovarian carcinoma (HGSC) are few, and the prognostic impact is unclear. We investigated mature TLS (mTLS), immature TLS (iTLS) and lymphoid aggregates (LA) in primary adnexal tumors (PTs) and synchronous omental/peritoneal metastases (pMets) of HGSC.
View Article and Find Full Text PDFGa-DOTA-FAPI-04 and F-FDG PET/CT: a head-to-head comparison for peritoneal carcinomatosis diagnostic accuracy.
Abdom Radiol (NY)
January 2025
Department of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, 12 Jiankang Road, Shijiazhuang, 050011, Hebei, China.
Purpose: The study aimed to compare the diagnostic accuracy of Ga-DOTA-FAPI-04 (Ga-FAPI) and F-FDG PET/CT for peritoneal carcinomatosis (PC) in patients with various types of cancer.
Methods: The study enrolled 113 patients with suspected peritoneal malignancy, each of whom underwent Ga-FAPI and F-FDG PET/CT scans. Lesions in all patients were confirmed through pathology or radiological follow-up.
Establishment of permanent peritoneal PleurX catheter as palliative treatment of malignant ascites.
Dan Med J
November 2024
Department of Gastrointestinal Surgery, Aarhus University Hospital.
Introduction: Refractory malignant ascites (RMA) is a manifestation of end-stage cancer disease with a major impact on quality of life due to the symptom burden and need for repeated hospitalisations. We previously described the implantation of the permanent PleurX catheter as a treatment of RMA. The present study aimed to evaluate and describe our experience with the permanent PleurX catheter system in the largest cohort to date.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!